Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 11/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 10/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 7/20 | 0.72 |
| ▸ | HTR1A | P08908 | 6/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.72 |
| ▸ | DRD2 | P14416 | 5/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.72 |
| ▸ | DRD1 | P21728 | 5/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.72 |
| ▸ | DRD3 | P35462 | 5/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.72 |
| ▸ | THPO | P40225 | 5/20 | 0.72 |
| ▸ | MTOR | P42345 | 5/20 | 0.72 |
| ▸ | TSHR | P16473 | 5/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385444 | 1.00 | CYP2D6 (1.00) | CYP2D6CYP1A2ALDH1A1TP53HTR1A | |
| SCHEMBL13305271 | 0.88 | CYP1A2 (0.78) | CYP2D6CYP1A2ALDH1A1TP53HTR1A | |
| Promazine SCHEMBL9052694 | 0.85 | CYP2D6 (1.00) | CYP2D6CYP1A2ALDH1A1TP53HTR1A | |
| Promazine SCHEMBL140489 | 0.85 | CYP2D6 (1.00) | CYP2D6CYP1A2ALDH1A1TP53HTR1A | |
| Promazine SCHEMBL29392545 | 0.85 | CYP2D6 (1.00) | CYP2D6CYP1A2ALDH1A1TP53HTR1A | |
| SCHEMBL9678540 | 0.85 | CYP1A2 (0.73) | CYP2D6CYP1A2ALDH1A1TP53HTR1A | |
| SCHEMBL13305247 | 0.84 | CYP1A2 (0.73) | CYP2D6CYP1A2ALDH1A1TP53HTR1A | |
| Promazine SCHEMBL123418 | 0.84 | LMNA (1.00) | CYP2D6CYP1A2ALDH1A1TP53HTR1A | |
| Promazine SCHEMBL29390978 | 0.84 | LMNA (1.00) | CYP2D6CYP1A2ALDH1A1TP53HTR1A | |
| Promazine SCHEMBL27425063 | 0.84 | CYP2D6 (0.97) | CYP2D6CYP1A2ALDH1A1TP53HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1976723-A | Treatment of infectious diseases | BKG PHARMA APS (DK) | 2007-06-06 | — | — | CN | claimed |
| US-20130204238-A1 | COMBINATION THERAPY | FOLLICA, INC (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2552323-A1 | COMBINATION THERAPY | Follica, Inc. (US) | 2013-02-06 | — | — | EP | disclosed |
| US-8252749-B2 | Methods, kits, and compositions for generating new hair follicles and growing hair | FOLLICA, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120156228-A1 | Methods, Kits, and Compositions for Generating New Hair Follicles and Growing Hair | FOLLICA, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012067630-A1 | HAIR GROWTH TREATMENT | FOLLICA, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012067631-A1 | BODY SURFACE TREATMENT | FOLLICA, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012067632-A1 | SEQUENTIAL BODY SURFACE TREATMENT | FOLLICA, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-1670427-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | CombinatoRx, Incorporated (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1599212-A4 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1599212-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050192261-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INCORPORATED | 2005-09-01 | — | — | US | disclosed |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050112199-A1 | Therapeutic regimens for administering drug combinations | COMBINATORX, INCORPORATED | 2005-05-26 | — | — | US | disclosed |
| WO-2005030132-A2 | THERAPEUTIC REGIMENS FOR ADMINISTERING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005027839-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2004-11-11 | — | — | US | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192261-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, CMA1, CCL11 | CYP2D6 835/4885CYP1A2 668/4885ALDH1A1 749/4885 |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | HLA-DRB1, TSLP, SERPINA6 | CYP2D6 501/4885CYP1A2 773/4885ALDH1A1 2701/4885 |
| US-20120156228-A1 | Methods, Kits, and Compositions for Generating New Hair Follicles and Growing Hair | NGF, HDGF, SHH | CYP2D6 4169/4885CYP1A2 3033/4885ALDH1A1 3080/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | CYP2D6 981/4885CYP1A2 1083/4885ALDH1A1 1014/4885 |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | CYP2D6 981/4885CYP1A2 1083/4885ALDH1A1 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.